XERS — Xeris Biopharma Holdings Share News
0.000.00%
Last trade - 00:00- $1.84bn
- $1.97bn
- $291.85m
Brief: Xeris Biopharma Announces First Participant Dosed In A Phase 2 Clinical Study Of Its Investigational Subcutaneous Levothyroxine In Patients With Hypothyroidism
Xeris Biopharma Holdings Inc reports results for the quarter ended in March - Earnings Summary
Brief: Xeris Biopharma Q1 product revenue USD 32.265 million
Brief: Xeris Biopharma Reports Q1 2023 Financial Results
Xeris Biopharma Holdings Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Xeris Biopharma Announces Issuance Of US Patent Covering Xerisol Formulations
U.S. STOCKS ON THE MOVE-Piedmont Lithium, Walmart, Kilroy Realty
U.S. STOCKS ON THE MOVE-Walmart, JD.Com, Crinetics
U.S. STOCKS ON THE MOVE-Neogen Corp, Freight Technologies, Philip Morris
Brief: Xeris Biopharma Announces Research Evaluation Collaboration Agreement With Regeneron
Xeris Biopharma climbs on research collaboration with Regeneron
Brief: Xeris Biopharma Appoints Ricki Fairley To Board Of Directors
Xeris Biopharma Holdings Inc reports results for the quarter ended in December - Earnings Summary
Xeris Bio rises on upbeat 2022 results
Brief: Xeris Biopharma Reports Fourth Quarter And Full-Year 2022 Financial Results
Brief: Xeris Biopharma Reports Q4 basic Shr Loss $0.10
Xeris Biopharma Holdings Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-American Express, Genius Group
U.S. STOCKS ON THE MOVE-Chipmakers, C4 Therapeutics, energy sector